Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01901679 · ClinicalTrials.gov registry record · Early Phase 1
Celecoxib Inhibition of Aromatase Expression and Inflammation in Adipose Tissue of Obese Postmenopausal Women
A Early Phase 1 study of Obesity, sponsored by Rockefeller University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT01901679: Completed Early Phase 1 study of Obesity, sponsored by Rockefeller University.
NCT01901679 is a Early Phase 1 study of Obesity that has completed, run by Rockefeller University. The registered enrollment target is 10 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01901679, a Early Phase 1 study of Obesity, has completed, sponsored by Rockefeller University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The study plans to find out whether Celebrex may be potentially useful to decrease inflammation in fat tissues and thereby lower the production of substances such as estrogens that may increase the risk of developing breast cancer and lead to a poor outcome of the disease.
Primary Outcome
Study endpoint is a reduction in PGE-M in urine after treatment with celebrex
Conditions Studied
Interventions
- DRUG Celebrex
Study Locations (1)
New York
- The Rockefeller University - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2013-07 |
| Est. Completion | 2014-08 |
| Phase | Early Phase 1 |
What the finished NCT01901679 record still lists
NCT01901679 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 1 intervention - of which Celebrex is the first listed.
NCT01901679 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT01901679 about?
NCT01901679 is a clinical study titled "Celecoxib Inhibition of Aromatase Expression and Inflammation in Adipose Tissue of Obese Postmenopausal Women". The study plans to find out whether Celebrex may be potentially useful to decrease inflammation in fat tissues and thereby lower the production of substances such as estrogens that may increase the risk of developing breast cancer and lead to a poor outcome of the disease.
What is the current status of trial NCT01901679?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2013-07. Estimated completion is 2014-08.
What conditions does trial NCT01901679 study?
This clinical trial studies the following conditions: Obesity.
What interventions are being tested in trial NCT01901679?
The interventions under investigation include: Celebrex (DRUG).
Who is sponsoring clinical trial NCT01901679?
This trial is sponsored by Rockefeller University, which has 117 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01901679 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01901679's enrollment target sits among peer trials
10 1025th of 1053 higher than 19 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Regional Lipolysis and Adipocyte Lipolysis Protein Stimulation
RECRUITING · Early Phase 1
-
Cardiovascular Effects of Angiotensin-(1-7) in Obesity Hypertension
RECRUITING · Early Phase 1
-
Social Determinants of Sleep and Obesity
RECRUITING · Early Phase 1
-
Effect of Tirzepatide on Markers of MASLD in Patients With Obesity
RECRUITING · Early Phase 1
-
Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues
RECRUITING · Early Phase 1
-
Evaluation of Milk Polar Lipids in Dyslipidemic Adults With Abdominal Obesity
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia